Functions of WW domains in the nucleus  by Sudol, Marius et al.
Minireview
Functions of WW domains in the nucleus
Marius Sudola;*, Krzysztof Sliwab, Tommaso Russoc
aDepartment of Medicine, Mount Sinai Medical Center, New York, NY 10029, USA
bDepartment of Physics and Astronomy, Tufts University, Medford, MA 02155, USA
cDepartment of Biochemistry and Medical Biotechnology, University of Naples, ‘Federico II’, Naples I-80131, Italy
Received 3 January 2001; accepted 9 January 2001
First published online 19 January 2001
Edited by Gianni Cesareni
Abstract The WW domain is a protein module found in a wide
range of signaling proteins. It is one of the smallest protein
modules that folds as a monomer without disulfide bridges or
cofactors. WW domains bind proteins containing short linear
peptide motifs that are proline-rich or contain at least one proline.
Although the WW domain was initially considered a ‘cytoplasmic
module’, the proteins containing WW domains have also been
localized in the cell nucleus. Moreover, these proteins have been
documented to participate in co-activation of transcription and
modulation of RNA polymerase II activity. The carboxy-terminal
domain (CTD) of RNA polymerase II acts as an assembly
platform for distinct WW domain-containing proteins that affect
the function of the RNA polymerase II. The formation of
complexes between CTD and WW domain-containing proteins is
regulated by phosphorylation of the CTD. Since the CTD
sequence is highly repetitive and a target of several post-
translational modifications and conformational changes, it
presents a unique structure capable of enormous molecular
diversity. The WW domain has been implicated in several human
diseases including Alzheimer’s disease. The WW domain-contain-
ing iso-prolyl isomerase named Pin1, a protein known to be
essential for cell cycle progression, was shown to be active in
restoration of the microtubule-binding activity of Tau, a protein
of neurofibrillar tangles found in the brains of Alzheimer’s
patients. It is the WW domain of Pin1 that interacts directly with
Tau protein. In addition, the WW domain-containing adapter
protein FE65 was shown to regulate processing of Alzheimer’s
amyloid precursor protein. It is expected that by understanding
the details of the WW domain-mediated protein^protein inter-
actions, we will be able to illuminate numerous signaling path-
ways which control certain aspects of transcription and cell
cycle. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. WW domain as a protein module
WW domains are small modules composed of 40 amino
acids. The name refers to two signature tryptophan (W) res-
idues that are spaced 20^22 amino acids apart and play an
important role in its structure and function [1]. The delinea-
tion of the WW domain was prompted by the identi¢cation of
repeated sequences in the murine isoform of Yes kinase-asso-
ciated protein (YAP) [1]. Functionally, the WW domain re-
sembles the Src homology domain 3, a protein module orig-
inally identi¢ed by homology to the amino-terminal region of
Src protein (SH3 domain) by displaying a⁄nity toward pro-
line-rich or proline-containing ligands [2]. Recent studies have
shown that certain molecular details of the domain^ligand
complex are similar for SH3 and WW domains [3]. The struc-
ture of the WW domain reveals a compact antiparallel three-
stranded-L-sheet that forms a shallow interface for binding
linear peptide motifs of the ligands [4,5]. Based on the ligand
predilection, WW domains fall into two major and two minor
groups [6]. One major group (Group I) binds polypeptides
with the minimal core consensus PPxY, and the other binds
ligands with PPLP motif (Group II). Group III WW domains
select poly-P motifs £anked by R or K, whereas Group IV
WW domains bind to short sequences with phospho-S or
phospho-T followed by P, in a phosphorylation-dependent
manner [6].
The Kd of interaction for WW^ligand complex formation is
in the high nM to low WM values for proline-rich ligands, and
in the low WM values for phospho-SP- or phospho-TP-con-
taining ligands. Phosphorylation of the terminal tyrosine in
the ligand PPxY for Group I WW domains abolishes the
binding in vitro, and possibly in vivo, suggesting that this
modi¢cation could represent a negative regulation mechanism
for a large subset of WW domains [6].
Shortly after its characterization, WW domain attracted
attention because the signaling complexes it mediates have
been implicated directly or indirectly in several human dis-
eases including Liddle’s syndrome of hypertension, muscular
dystrophy, Alzheimer’s and Huntington’s diseases, and, more
recently, cancer [6,7]. In the case of Alzheimer’s disease, dis-
cussed herein, the implicated WW domains interface with cell
cycle and transcription; and the binding speci¢city of one of
the WW domains, Pin1, was illuminated with the help of anti-
body speci¢c for phospho-epitopes found on mitotic proteins.
This brief contribution focuses on one aspect of WW do-
main, speci¢cally its role in the nuclear processes. Many facets
of the WW domain function in the nucleus are just emerging
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and prevent us from presenting a uniform picture of signaling
steps mediated by WW domains acting in nucleus. Neverthe-
less, this study should serve as a useful summary of what is
currently known about the role of WW domain-based inter-
actions in regulating transcription and the cell cycle. Addi-
tionally, we hope this review will stimulate interest in the ¢eld
and serve as a harbinger of new observations.
2. WW domain and transcription
Among several examples of WW domain complexes func-
tioning in the cell nucleus, the best documented one is the
physical and functional complex formed between the WW
domain of YAP and the PEBP2 (polyoma enhancer binding
protein 2) transcription factor, in which the YAP WW do-
main acts as a transcriptional co-activator through interaction
with a PPPY motif in PEBP2 [8] (Fig. 1). The PPxY motif has
been observed in a number of transcription factors including
NF-E2, AP2, and c-Jun, where it may play a role in transcrip-
tional activation. For example, the hematopoietic transcrip-
tion factor, NF-E2, contains two PPxY motifs, which can be
recognized by the WW domains of E3 ubiquitin ligases [9].
Interaction of WW domain-containing proteins with this mo-
tif seems to be important for transcriptional activation, as
mutant constructs expressing one of the two PPxY motifs in
NF-E2 or the single mutated copy in PEBP2 are defective in
their co-transcriptional activity [9]. It is speculated that the
presence of the PPxY motif within transcription factors may
recruit WW domain-containing proteins such as Npw38 or
YAP, which have been known to act as transcriptional co-
activators. Perhaps negative regulation of transcription by
certain WW domains or by WW domain-containing proteins
is also possible. PQBP-1, a novel polyglutamine tract binding
protein with an WW domain, was shown to inhibit activation
of transcription by Brn-2 [10] (Fig. 1).
3. WW domains, RNA polymerase II and cell cycle
The cell cycle and transcription by RNA polymerase II are
closely related because they employ shared components [11].
The transcriptional activity of RNA polymerase II large sub-
unit (RNA Pol II) is modulated during cell cycle. The phos-
phorylation status of the carboxy-terminal domain (CTD) of
the largest subunit of RNA Pol II is cell cycle dependent and
correlates with changes in transcription [11]. Several CTD ki-
nases are also members of the cyclin-dependent kinase (cdk)
family including cdk1, cdk7, cdk8, and cdk9. Each of these
cdks, have been directly linked to the cell cycle regulatory
events [11]. Other CTD kinases such as casein kinase II, and
protein-tyrosine kinases such as c-Abl and Arg, have also
been implicated in cell cycle modi¢cations of the CTD. There-
fore the same enzymes target and coordinate functionally
linked events of cell cycle and RNA Pol II-regulated tran-
scription.
Within the RNA Pol II largest subunit, the CTD is the
primary target of phosphorylation. In the M-phase where
transcription is globally inhibited, CTD is hyperphosphory-
lated in part by cdk1. In G1 phase, CTD phosphorylation
on S and T is somewhat lower. In the G1/S phase transition,
protein-tyrosine kinase activity of c-Abl toward CTD in-
creases [11].
The CTD of mammalian RNA polymerase II largest sub-
unit contains 52 tandem repeats of a heptapeptide with the
consensus sequence, YSPTSPS. These heptapeptides may be
either perfect or imperfect iterations of the consensus hepta-
peptide [11]. Gavva and colleagues were the ¢rst to show that
WW domain-containing proteins such us Nedd4 and YAP
could interact with RNA Pol II CTD even though CTD con-
tained only partial PPxY motif (xPxY) [12]. Being a part of
the repeated heptamers (YSPTSPSYSPTSPS) the PSY motif
of CTD is present at a relatively high local concentration [13].
Subsequently, work from several laboratories, including ours,
has demonstrated that CTD of RNA Pol II could bind vari-
ous WW domain-containing proteins and that the binding
was regulated by phosphorylation [6]. Ess1/Pin1 PPIase was
shown to interact with the phosphorylated form of CTD,
whereas Rsp5/Nedd4 ubiquitin ligase was documented to in-
teract preferentially with unphosphorylated CTD [6,9,13].
Phosphorylation of CTD seems to play a role of a switch
that selects which WW domain-containing proteins could as-
semble on the CTD tail. These exclusive complexes seem to
correlate with distinct functions of RNA Pol II. For example,
binding of Ess1/Pin1 to CTD of RNA Pol II may regulate the
process of RNA termination. Complex of the CTD with
Rsp5/Nedd4 is proposed to initiate degradation of RNA poly-
merase II by the ubiquitin-proteasome pathway [6] (Fig. 1). A
number of other proteins with modular domains are known to
nucleate on the CTD tail giving this essential part of RNA Pol
II an important regulatory function. Indeed, considering the
growing importance of the CTD of RNA Pol II as a sensor of
numerous signaling pathways, the CTD is ‘the tail that wags
the dog’ [14].
4. Potential diversity at the CTD of RNA Pol II
We know that CTD is a target of S, T, and Y phosphory-
lation, that Ess1/Pin1 peptidyl-prolyl cis/trans isomerase cata-
lyzes the cis/trans conversion of the peptide bonds between
phospho-S/T and P, and that O-glycosylation of S and T
residues of CTD was documented and shown to be reciprocal
with phosphorylation [11,15,16]. We therefore decided to cal-
culate the number of potential variants that the highly re-
Fig. 1. Examples of WW domain-mediated complexes in the nucleus. The WW domain of Yes kinase-Associated Protein (YAP) binds Polyoma
Enhancer Binding Protein 2 (PEBP2) acting as a co-activator of transcription (panel 1 and [8]). The WW domain-containing protein Np/PQ
(named after two identical but independently characterized proteins Npw38 and PQBP1) binds to the poly Q region of transcription factor
BRN-2 inhibiting transcription (panel 2, [10,39,40]). Carboxy-Terminal Domain (CTD) of RNA Pol II forms a complex with WW domains of
mammalian Nedd4 (Rsp5 is the yeast homolog of Nedd4) protein that contains ubiquitin ligase activity (Hect domain). Formation of this com-
plex leads to the degradation of RNA Pol II (panel 3, [6]). Phosphorylated CTD binds to the WW domain of Pin1 (Ess1 is the yeast homolog
of Pin1) protein that contains iso-prolyl isomerase activity. Formation of this complex is correlated with transcriptional termination (panel 4,
[6]). Phospho-CTD interacts with WW domains of a splicing factor Prp40 resulting in regulation of RNA processing (panel 5, [41]). Elongation
of transcript is co-regulated by complex between phospho-CTD and CA150 adapter protein. Here the complex between phospho-CTD and
CA150 is mediated by FF domains (panel 6, [42]).
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peated heptapeptide sequence of CTD could form. For our
calculations we took only perfect heptapeptide repeats and
ignored imperfect iterations. In the human CTD, there are
21 perfect repeats and in the yeast CTD there are 19 perfect
repeats.
We considered a single YSPTSPS heptamer. Within the
YSPTSPS heptamer, Y, Ss and T may be modi¢ed by phos-
phorylation. Each of Y, S and T can independently acquire
one of two forms: phosphorylated and/or not phosphorylated.
The number of possible variants of the YSPTSPS heptamer
due to phosphorylation is 32 (each of ¢ve Y, S and T can
appear in two variants: 25 = 32).
Since we assume that each of the YSPTSPS heptamers is
independent of any other in the entire CTD, the number of
possible variants of CTD due to phosphorylation is 32N ,
where N is the number of repeats of YSPTSPS heptamers in
the entire CTD.
Using the same tools we calculated the number of possible
variants due to O-glycosylation of S and T, as well as the
number of possible variants of CTD due to alternative
cis/trans conformations of S^P bonds (Table 1).
A surprisingly large number of variants was revealed when
we took into account all three possible modi¢cations to the
YSPTSPS heptamer described above. The Y can appear in
two forms (phosphorylated and/or not phosphorylated);
each S and T may appear in three forms (phosphorylated,
glycosylated or unmodi¢ed) and each of S^P peptide bond
may appear in two forms (cis or trans). The number of pos-
sible variants of YSPTSPS due to all three modi¢cations is
648; (2U3U3U3U3U4 = 648).
Since each of the YSPTSPS heptamers is considered inde-
pendent of any other in the entire CTD, the number of pos-
sible variants of CTD due to all three modi¢cations is 648N ,
where N is the number of repeats of YSPTSPS heptamers in
the entire CTD (Table 1).
Indeed, the numbers are astronomical, and they would be
signi¢cantly higher if the imperfect repeats (e.g. additional 31
for the human RNA Pol II CTD) were included. The purpose
of this academic exercise is to illuminate a tremendous poten-
tial of CTD sequences for forming unique structural and bio-
chemical micro-environments. Probably the number of con-
formations, shapes or variants that are ‘meaningful’ or
‘read’ by the CTD interacting proteins is smaller. For exam-
ple, phosphorylation or glycosylation may favor one particu-
lar conformation of the S^P peptide bonds within the CTD.
The biological response could be initiated only if the stoichi-
ometry of interacting proteins is reached; e.g. half of the CTD
tail has to be occupied by binding partners or it has to assume
a certain conformation in order for the RNA Pol II to change
its activity. Without any doubt, the CTD of RNA Pol II
remains an exciting challenge for experimental biology.
5. WW domains of Pin1 and Fe65 in Alzheimer’s disease
A monoclonal antibody called mitotic phosphoprotein
monoclonal-2 (MPM-2) has been an important tool for dis-
secting the role of phosphorylation in mitotic regulation [17].
It is through the use of the MPM-2 antibody that the con-
nection between RNA Pol II CTD, cell cycle and one aspect
of protein regulation in Alzheimer’s disease has surfaced [11].
The MPM-2 antibody recognizes a phosphorylated epitope:
phospho-S- or phospho-T-P epitope on ca. 50 proteins, which
are localized to various mitotic structures [17]. MPM-2 anti-
body helped to uncover the novel binding function of Pin1
WW domain [11]. Pin1 and MPM-2 were shown to recognize
phosphorylated CTD as well as phosphorylated Tau protein
[11,18]. Tau, a microtubule-associated protein is an important
component of neuro¢brillary tangles present in the Alzheim-
er’s brain. Tau as a component of neuro¢brillary tangle is
hyperphosphorylated and its phosphorylation causes a loss
of Tau binding to microtubules. It was also shown that
Pin1 has the ability to bind to phospho-T-P motif in Tau
and restore Tau’s ability to promote microtubule assembly
in vitro [18].
Since changes in the phosphorylation status of RNA Pol II
in Alzheimer’s brain have been detected and Tau is hyper-
phosphorylated in the neuro¢brillary tangles of Alzheimer’s
brain, it should be of interest to study the Pin1 WW domain
in detail. The isolation of low molecular weight, non-peptide
compounds that interact with the WW domain of Pin1 or the
Pin1 protein and modulate its activity in neurons, would pro-
vide valuable reagents for basic and applied study.
Fe65 is one of three adapter proteins interacting with the
cytodomain of Alzheimer’s L-amyloid precursor protein
(APP) [19]. APP is an integral membrane protein from which
the Alzheimer’s L-amyloid peptide (AL) derives as a conse-
quence of its proteolytic processing [20]. This amyloidogenic
processing is a¡ected by the interaction of APP with Fe65 and
with the other two PTB-containing ligands, X11 [21] and
mDab1 [22]. The overexpression of Fe65 causes an increased
generation of AL in cultured cells, [23,24] while overexpres-
sion of X11 inhibits the proteolytic processing of APP [25^27].
The WW domain of Fe65 binds several proteins, one of which
is Mena, the mammalian orthologue of the product of the
enabled gene of Drosophila, which is a genetic modulator of
the phenotype induced by the Abl gene mutation in Drosophi-
la [28]. The Drosophila Abl gene has a neuronal function and
it is required for axonal outgrowth and fasciculation. The
detection of Fe65^Mena/(enabled) protein complex is of par-
ticular interest, considering that mDab1 is the orthologue of
the disabled gene of Drosophila, another modulator of the Abl
mutation induced phenotype, whose action is counteracted by
enabled [29]. The possible competition between mDab1 and
Table 1
Molecular diversity of the yeast and human CTD of RNA polymerase II
Yeast CTD Human CTD
Number of repeats of YSPTSPS in the CTD 19 21
Number of possible variants of CTD due to phosphorylation of Y, S and T positions 3.961U1028 4.056U1031
Number of possible variants of CTD due to glycosylation of S and T positions 7.556U1022 1.934U1025
Number of possible variants of CTD due to alternative conformations of S^P peptide bonds
(cis and trans)
2.749U1011 4.398U1012
Number of possible variants of CTD due to phosphorylation, glycosylation and alternative
conformations of S^P peptide bonds
2.630U1053 1.104U1059
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the Fe65^Mena complex for the binding to APP could explain
the opposite e¡ects of enabled and disabled gene products in
vivo.
Besides its involvement in the protein^protein interaction
network centered at the cytosolic domain of APP, Fe65 has
also been studied for its possible role in the regulation of
transcription. Early results on this protein showed that it is
able to strongly activate the transcription of a reporter gene
when fused to an heterologous DNA binding domain [30].
More recently it was found that Fe65, through its PTB1 do-
main, forms complexes, in vitro and in vivo, with the tran-
scription factor CP2/LSF/LBP1 and that these complexes are
present both in the cytoplasm and in the nucleus [31]. This
observation has acquired new signi¢cance following the dis-
covery that CP2/LSF/LBP1 gene is a genetic determinant of
Alzheimer’s disease [32]. In fact, by examining 1139 Alzheim-
er’s disease cases and 1317 controls, it was demonstrated that
a GHA polymorphism in the 3P-UTR of the CP2/LSF/LBP1
gene on chromosome 12 is associated with a modi¢ed risk of
Alzheimer’s disease. Individuals bearing one or two adenine
alleles have a signi¢cantly lower risk of Alzheimer’s disease
than the subjects with the guanine^guanine genotype [32].
This observation suggests the existence of a functional link
between AL generation from APP and the CP2/LSF/LBP1
factor ^ the tool of this link being Fe65. In support of this
hypothesis, there is a recent evidence that Fe65 is targeted to
the nucleus and that this phenomenon is regulated by APP,
which functions as a cytoplasmic anchor preventing the Fe65
nuclear translocation [33]. Experiments based on the use of
deletion mutants of Fe65 allowed us to demonstrate that a
region of about 100 amino acids, containing the WW domain,
is responsible for Fe65 nuclear targeting and that the same
region is also su⁄cient to target to the nucleus a reporter
protein, otherwise restricted to the cytoplasm. Considering
that no known nuclear localization signal (NLS) is present
in these 100 amino acids, it can be speculated that the trans-
location of Fe65 into the nucleus takes place by means of a
cargo system and that the WW domain is involved in the
docking of Fe65 to the nuclear-targeted cargo. There are sev-
eral examples of proteins imported to the nucleus in the ab-
sence of any canonical NLS [34]. The question is how these
proteins interact with the translocation machinery. As men-
tioned above, the WW domain of Fe65 interacts with several
proteins, only one of which has been identi¢ed. In the light of
the possible involvement of this WW domain in the nuclear
targeting of Fe65, the identi¢cation of its ligands could lead to
the discovery of new mechanisms of cytosol-nuclear tra⁄ck-
ing not based on the classical NLS motif.
6. WW domain as an emerging therapeutic target
Since the WW domain is small and its ligand is rigid and
well-structured, the WW domain^ligand complex is amenable
for gene and drug therapy [35,36]. Small non-peptide com-
pounds, perhaps mimicking N-substituted amino acids [3],
may act as stimulators or inhibitors of signaling steps medi-
ated by WW domain. Moreover, we are now in a position to
use molecular repertoires to tailor individual WW domains
toward new binding and signaling activities [37].
With the imminent advent of the WW domain proteomic
chip based on a unique feature of the WW domain, namely its
ability to form an active domain when chemically synthesized
on solid support as in the case of the SPOT membrane assay
([38] and Sudol, M., submitted) we should be able to identify
speci¢c signaling targets for development of useful therapeu-
tics.
Acknowledgements: We would like to thank our colleagues Daniela
Barila, Kate Biblowitz, Giovanni Blandino, Maria Macias and Josh
Rappoport for valuable comments on the manuscript. Special thanks
go to the organizers of the workshop on ‘Making Decisions in G1P,
held in Frascati, Italy in October 2000. This conference created a
productive and stimulating forum, which opened new and valuable
collaborations for our laboratories. This work was supported by
Grants from NIH (AR45626) Human Frontier Science Program
Organization (RG234), from Alzheimer’s Association (RG99-1670)
awarded to M.S. and from EU V Framework Program (QLRT-
1999-2238) to T.R.
References
[1] Bork, P. and Sudol, M. (1994) Trends Biochem. Sci. 19, 531^
533.
[2] Chen, H.I. and Sudol, M. (1995) Proc. Natl. Acad. Sci. USA 92,
7819^7823.
[3] Zarrinpar, A. and Lim, A.W. (2000) Nature Struct. Biol. 7, 611^
613.
[4] Macias, M.J., Hyvonen, M., Baraldi, E., Schultz, J., Sudol, M.,
Saraste, M. and Oschkinat, H. (1996) Nature 382, 646^649.
[5] Huang, X., Roy, F., Zhang, R., Joachiamiak, A., Sudol, M. and
Eck, M.J. (2000) Nature Struct. Biol. 7, 634^638.
[6] Sudol, M. and Hunter, T. (2000) Cell 103, 1001^1004.
[7] Sudol, M. (1998) Oncogene 17, 1469^1474.
[8] Yagi, R., Chen, L.F., Shigesada, K., Murakami, Y. and Ito, Y.
(1999) EMBO J. 18, 2551^2562.
[9] Kay, B.K., Williamson, M.P. and Sudol, M. (2000) FASEB J. 14,
231^241.
[10] Waragai, M., Lammers, C.H., Takeuchi, S., Iamfuku, I., Udaga-
wa, Y., Kanazawa, I., Kawabata, M., Mouradian, M.M. and
Okazawa, H. (1999) Hum. Mol. Genet. 8, 977^987.
[11] Bregman, D.B., Pestell, R.G. and Kidd, V.J. (2000) Front. Bio-
sci. 5, 244^257.
[12] Gavva, N.R., Gavva, R., Ermekova, K., Sudol, M. and Shen,
C.K.J. (1997) J. Biol. Chem. 272, 24105^24108.
[13] Chang, A., Cheang, S. and Espanel, X. (2000) J. Biol. Chem. 275,
20562^20571.
[14] Steinmetz, E.J. (1997) Cell 89, 491^494.
[15] Shen, M., Stukenberg, T.P., Kirschner, M.C. and Lu, K.P. (1998)
Genes Dev. 12, 706^720.
[16] Comer, F.I. and Hart, G.W. (2000) J. Biol. Chem. 275, 29179^
29182.
[17] Davis, F.M., Tsao, T.Y., Fowler, S.K. and Rao, P.N. (1983)
Proc. Natl. Acad. Sci. USA 80, 2926^2930.
[18] Lu, P.J., Wulf, G., Zhu, X.Z., Davies, P. and Lu, P.K. (1998)
Nature 399, 784^788.
[19] Russo, T., Faraonio, R., Minopoli, G., De Candia, P., De
Renzis, S. and Zambrano, N. (1998) FEBS Lett. 434, 1^7.
[20] Selkoe, D.J. (1999) Nature 369 (Suppl. 6738), A23^A31.
[21] Borg, J.P., Ooi, J., Levy, E. and Margolis, B. (1996) Mol. Cell.
Biol. 16, 6229^6241.
[22] Homayouni, R., Rice, D.S., Sheldon, M. and Curran, T. (1999)
J. Neurosci. 19, 7507^7515.
[23] Sabo, S.L., Lanier, L.M., Ikin, A.F., Khorkova, O., Sahasra-
budhe, S., Greengard, P. and Buxbaum, J.D. (1999) J. Biol.
Chem. 274, 7952^7957.
[24] Guenette, S.Y., Chen, J., Ferland, A., Haas, C., Capell, A. and
Tanzi, R.E. (1999) J. Neurochem. 73, 985^993.
[25] Tomita, S., Ozaki, T., Taru, H., Oguchi, S., Takeda, S., Yagi, Y.,
Sakiyama, S., Kirino, Y. and Suzuki, T. (1999) J. Biol. Chem.
274, 2243^2254.
[26] Borg, J.P., Yang, Y.N., De Tadde¤o-Borg, M., Margolis, B. and
Turner, R.S. (1998) J. Biol. Chem. 273, 14761^14766.
[27] Sastre, M., Turner, R.S. and Levy, E. (1998) J. Biol. Chem. 273,
22351^22357.
[28] Ermekova, K-S., Zambrano, N., Linn, H., Minopoli, G., Gertler,
FEBS 24572 14-2-01 Cyaan Magenta Geel Zwart
M. Sudol et al./FEBS Letters 490 (2001) 190^195194
F., Russo, T. and Sudol, M. (1997) J. Biol. Chem. 272, 32869^
32874.
[29] Gertler, F.B., Comer, A.R., Juang, J.L., Ahern, S.M., Clark,
M.J., Lieb, E.C. and Ho¡mann, F.M. (1995) Genes Dev. 9,
521^533.
[30] Duilio, A., Zambrano, N., Mogavero, A.R., Ammendola, R.,
Cimino, F. and Russo, T. (1991) Nucleic Acids Res. 19, 5269^
5274.
[31] Zambrano, N., Minopoli, G. and de Candia, P. (1998) J. Biol.
Chem. 273, 20128^20133.
[32] Lambert, J.C., Goumidi, L., Vrieze, F.W., Frigard, B., Harris,
J.M., Cummings, A., Coates, J., Pasquier, F., Cottel, D., Gaillac,
M., St Clair, D., Mann, D.M., Hardy, J., Lendon, C.L.,
Amouyel, P. and Chartier-Harlin, M.C. (2000) Hum. Mol. Gen-
et. 9, 2275^2280.
[33] Minopoli, G., de Candia, P., Bonetti, A., Faraonio, R., Zambra-
no, N., and Russo T. (2000) J. Biol. Chem., in press.
[34] Ka¡man, A. and O’Shea, E.K. (1999) Annu. Rev. Cell Dev. Biol.
15, 291^339.
[35] Sudol, M. (1996) Prog. Biophys. Mol. Biol. 65, 113^132.
[36] Sudol, M. (1997) Emerg. Ther. Targets 1, 81^84.
[37] Espanel, X. and Sudol, M. (1999) J. Biol. Chem. 274, 17284^
17289.
[38] Sudol, M., Bork, P. and Chen, H. (2000) USA Patents
#6,022,740 and #6,034,212.
[39] Zhang, Y.-Z., Lindblom, T., Chang, A., Sudol, M., Sluder, A.E.
and Golemis, E.A. (2000) Gene 257, 33^43.
[40] Komuro, A., Saeki, M. and Kato, S. (1999) Nucleic Acids Res.
27, 1957^1965.
[41] Morris, D.P. and Greenleaf, A.L. (2000) J. Biol. Chem. 275,
39935^39943.
[42] Carty, S.M., Goldstrohm, A.C., Sune, C., Garcia-Blanco, M. and
Greenleaf, A.L. (2000) Proc. Natl. Acad. Sci. USA 97, 9015^
9020.
FEBS 24572 14-2-01 Cyaan Magenta Geel Zwart
M. Sudol et al./FEBS Letters 490 (2001) 190^195 195
